New study aims to spare thousands of breast cancer patients from unnecessary chemo
NCT ID NCT07379918
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking at a genomic test called EndoPredict that analyzes tumor genes to predict the risk of breast cancer returning. The goal is to see if women with a low-risk score can safely skip chemotherapy and only take hormone therapy. Researchers will follow 1,000 patients for 10 years to track relapse and survival rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EndoPredict genomic test
What this could lead to
If successful, this could help doctors safely skip chemotherapy for many women with early breast cancer, reducing side effects without increasing relapse risk.
What could go wrong
This is an observational study, not a treatment trial. It will gather real-world data but won't directly prove that skipping chemotherapy is safe for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Saint-Louis
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••